Role and mechanism of COL3A1 in regulating the growth, metastasis, and drug sensitivity in cisplatin-resistant non-small cell lung cancer cells

References

• Slatore C, Lareau SC, Fahy B. Staging of Lung Cancer. Am J Respir Crit Care Med. 2022;205(9):17–12. doi:10.1164/rccm.2059P17.
   PubMedGoogle Scholar
• Mithoowani H, Febbraro M. Non-small-cell lung cancer in 2022: a review for general practitioners in oncology. Curr Oncol. 2022;29(3):1828–1839. doi:10.3390/curroncol29030150.
   PubMed Web of Science ®Google Scholar
• Chen P, Liu Y, Wen Y, Zhou C. Non-small cell lung cancer in China. Cancer Commun (Lond). 2022;42(10):937–970. doi:10.1002/cac2.12359.
   PubMed Web of Science ®Google Scholar
• Kuivaniemi H, Tromp G. Type III collagen (COL3A1): gene and protein structure, tissue distribution, and associated diseases. Gene. 2019;707:151–171. doi:10.1016/j.gene.2019.05.003.
   PubMed Web of Science ®Google Scholar
• Kamali Zonouzi S, Pezeshki PS, Razi S, Rezaei N. Cancer-associated fibroblasts in colorectal cancer. Clin Transl Oncol. 2022;24(5):757–769. doi:10.1007/s12094-021-02734-2.
   PubMed Web of Science ®Google Scholar
• Yao G, Zhao K, Bao K, Li J. Radiation increases COL1A1, COL3A1, and COL1A2 expression in breast cancer. Open Med (Wars). 2022;17(1):329–340. doi:10.1515/med-2022-0436.
   PubMedGoogle Scholar
• Ucaryilmaz Metin C, Ozcan G. Comprehensive bioinformatic analysis reveals a cancer-associated fibroblast gene signature as a poor prognostic factor and potential therapeutic target in gastric cancer. BMC Cancer. 2022;22(1):692. doi:10.1186/s12885-022-09736-5.
   PubMed Web of Science ®Google Scholar
• Shen Y, Li X, Wang D, Zhang L, Li X, Su L, Fan X, Yang X. COL3A1: potential prognostic predictor for head and neck cancer based on immune-microenvironment alternative splicing. Cancer Med. 2023;12(4):4882–4894. doi:10.1002/cam4.5170.
   PubMed Web of Science ®Google Scholar
• Hosseini ST, Nemati F. Identification of GUCA2A and COL3A1 as prognostic biomarkers in colorectal cancer by integrating analysis of RNA-Seq data and qRT-PCR validation. Sci Rep. 2023;13(1):17086. doi:10.1038/s41598-023-44459-y.
   PubMed Web of Science ®Google Scholar
• Van Espen B, Oo HZ, Collins C, Fazil L, Molinolo A, Yip K, Murad R, Gleave M, Ronai ZE. RNF185 control of COL3A1 expression limits prostate cancer migration and metastatic potential. Mol Cancer Res. 2023;22(1):41–54. doi:10.1158/1541-7786.mcr-23-0512.
   Web of Science ®Google Scholar
• Yang F, Lin L, Li X, Wen R, Zhang X. Silencing of COL3A1 represses proliferation, migration, invasion, and immune escape of triple negative breast cancer cells via down-regulating PD-L1 expression. Cell Biol Int. 2022;46(11):1959–1969. doi:10.1002/cbin.11875.
   PubMed Web of Science ®Google Scholar
• Chen Y, Pan Y, Ji Y, Sheng L, Du X. Network analysis of differentially expressed smoking-associated mRnas, lncRnas and miRnas reveals key regulators in smoking-associated lung cancer. Exp Ther Med. 2018;16(6):4991–5002. doi:10.3892/etm.2018.6891.
   PubMed Web of Science ®Google Scholar
• Yu DH, Ruan XL, Huang JY, Liu XP, Ma HL, Chen C, Hu W-D, Li S. Analysis of the interaction network of hub miRnas-Hub genes, being involved in idiopathic pulmonary fibers and its emerging role in non-small cell lung cancer. Front Genet. 2020;11:11302. doi:10.3389/fgene.2020.00302.
   Web of Science ®Google Scholar
• Zhang M, Liang Y, Song P. COL3A1-positive endothelial cells influence LUAD prognosis and regulate LUAD carcinogenesis by NCL–PI3K–AKT axis. J Gene Med. 2023;26(1):e3573. doi:10.1002/jgm.3573.
   PubMed Web of Science ®Google Scholar
• Wang L, Sun Y, Guo Z, Liu H. COL3A1 overexpression associates with poor prognosis and cisplatin resistance in lung cancer. Balkan Med J. 2022;39(6):393–400. doi:10.4274/balkanmedj.galenos.2022.2022-6-16.
   PubMed Web of Science ®Google Scholar
• Singh A. RNA-binding protein kinetics. Nat Methods. 2021;18(4):335. doi:10.1038/s41592-021-01122-6.
   PubMed Web of Science ®Google Scholar
• Thiele BJ, Doller A, Kähne T, Pregla R, Hetzer R, Regitz-Zagrosek V. RNA-binding proteins heterogeneous nuclear ribonucleoprotein A1, E1, and K are involved in post-transcriptional control of collagen I and III synthesis. Circ Res. 2004;95(11):1058–1066. doi:10.1161/01.res.0000149166.33833.08.
   PubMed Web of Science ®Google Scholar
• Lambert SA, Jolma A, Campitelli LF, Das PK, Yin Y, Albu M, Chen X, Taipale J, Hughes TR, Weirauch MT, et al. The human transcription factors. Cell. 2018;172(4):650–665. doi:10.1016/j.cell.2018.01.029.
   PubMed Web of Science ®Google Scholar
• Di Martino JS, Nobre AR, Mondal C, Taha I, Farias EF, Fertig EJ, Naba A, Aguirre-Ghiso JA, Bravo-Cordero JJ. A tumor-derived type III collagen-rich ECM niche regulates tumor cell dormancy. Nat Cancer. 2022;3(1):90–107. doi:10.1038/s43018-021-00291-9.
   PubMedGoogle Scholar
• Rothamel K, Arcos S, Kim B, Reasoner C, Lisy S, Mukherjee N, Ascano M. ELAVL1 primarily couples mRNA stability with the 3′ UTRs of interferon-stimulated genes. Cell Rep. 2021;35(8):109178. doi:10.1016/j.celrep.2021.109178.
   PubMed Web of Science ®Google Scholar
• Hosea R, Hillary S, Wu S, Kasim V. Targeting transcription factor YY1 for cancer treatment: Current strategies and future directions. Cancers Basel. 2023;15(13):3506. doi:10.3390/cancers15133506.
   PubMed Web of Science ®Google Scholar
• Zhang X, Xu Y, Ma L, Yu K, Niu Y, Xu X, Shi Y, Guo S, Xue X, Wang Y, et al. Essential roles of exosome and circRNA_101093 on ferroptosis desensitization in lung adenocarcinoma. Cancer Commun (Lond). 2022;42(4):287–313. doi:10.1002/cac2.12275.
   PubMed Web of Science ®Google Scholar
• Meador CB, Hata AN. Acquired resistance to targeted therapies in NSCLC: updates and evolving insights. Pharmacol Ther. 2020;210:210107522. doi:10.1016/j.pharmthera.2020.107522.
   Web of Science ®Google Scholar
• Wang D, Zhao C, Xu F, Zhang A, Jin M, Zhang K, Liu L, Hua Q, Zhao J, Liu J, et al. Cisplatin-resistant NSCLC cells induced by hypoxia transmit resistance to sensitive cells through exosomal PKM2. Theranostics. 2021;11(6):2860–2875. doi:10.7150/thno.51797.
   PubMed Web of Science ®Google Scholar
• Lei T, Xu T, Zhang N, Zou X, Kong Z, Wei C, Wang Z. Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET/MYC/AXL axis. Pharmacol Res. 2023;188:188106668. doi:10.1016/j.phrs.2023.106668.
   Web of Science ®Google Scholar
• Zhang SW, Zhang N, Wang N. Role of COL3A1 and POSTN on pathologic stages of esophageal cancer. Technol Cancer Res Treat. 2020;19:191533033820977489. doi:10.1177/1533033820977489.
   Web of Science ®Google Scholar
• Han S, Wang Z, Liu J, Wang HD, Yuan Q. miR-29a-3p-dependent COL3A1 and COL5A1 expression reduction assists sulforaphane to inhibit gastric cancer progression. Biochem Pharmacol. 2021;188:188114539. doi:10.1016/j.bcp.2021.114539.
   Web of Science ®Google Scholar
• Zhou J, Yang Y, Zhang H, Luan S, Xiao X, Li X, Fang P, Shang Q, Chen L, Zeng X, et al. Overexpressed COL3A1 has prognostic value in human esophageal squamous cell carcinoma and promotes the aggressiveness of esophageal squamous cell carcinoma by activating the NF-κB pathway. Biochem Biophys Res Commun. 2022;613:193–200. doi:10.1016/j.bbrc.2022.05.029.
   PubMed Web of Science ®Google Scholar
• Palomo-Irigoyen M, Pérez-Andrés E, Iruarrizaga-Lejarreta M, Barreira-Manrique A, Tamayo-Caro M, Vila-Vecilla L, Moreno-Cugnon L, Beitia N, Medrano D, Fernández-Ramos D, et al. HuR/ELAVL1 drives malignant peripheral nerve sheath tumor growth and metastasis. J Clin Invest. 2020;130(7):3848–3864. doi:10.1172/jci130379.
   PubMed Web of Science ®Google Scholar
• Cai Z, Xu H, Bai G, Hu H, Wang D, Li H, Wang Z. ELAVL1 promotes prostate cancer progression by interacting with other m6A regulators. Front Oncol. 2022;12:12939784. doi:10.3389/fonc.2022.939784.
   Web of Science ®Google Scholar
• Kanzaki H, Chiba T, Kaneko T, Ao J, Kan M, Muroyama R, Nakamoto S, Kanda T, Maruyama H, Kato J, et al. The RNA-Binding protein ELAVL1 regulates hepatitis B virus replication and growth of hepatocellular carcinoma cells. Int J Mol Sci. 2022;23(14):7878. doi:10.3390/ijms23147878.
   PubMed Web of Science ®Google Scholar
• Mao G, Mu Z, Wu DA. Exosomal lncRNA FOXD3-AS1 upregulates ELAVL1 expression and activates PI3K/Akt pathway to enhance lung cancer cell proliferation, invasion, and 5-fluorouracil resistance. Acta Biochim Biophys Sin (Shanghai). 2021;53(11):1484–1494. doi:10.1093/abbs/gmab129.
   PubMed Web of Science ®Google Scholar
• Xie W, Wang Y, Zhang Y, Xiang Y, Wu N, Wu L, Li C, Cai T, Ma X, Yu Z, et al. Single-nucleotide polymorphism rs4142441 and MYC co-modulated long non-coding RNA OSER1-AS1 suppresses non-small cell lung cancer by sequestering ELAVL1. Cancer Sci. 2021;112(6):2272–2286. doi:10.1111/cas.14713.
   PubMed Web of Science ®Google Scholar
• Wang M, Mao C, Ouyang L, Liu Y, Lai W, Liu N, Shi Y, Chen L, Xiao D, Yu F, et al. Long noncoding RNA LINC00336 inhibits ferroptosis in lung cancer by functioning as a competing endogenous RNA. Cell Death Differ. 2019;26(11):2329–2343. doi:10.1038/s41418-019-0304-y.
   PubMed Web of Science ®Google Scholar
• Ali A, Ali A, Devi HS, Daddam JR, Sarwar R, Badrealam FK. The HDAC2/YY1/c-myc signaling axis regulates lung cancer cell migration and proliferation. Environ Toxicol. 2023;38(8):1989–2001. doi:10.1002/tox.23825.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Chen B, Pan H, Sun L, Yu T. PLIC11 drives lung cancer progression through regulating the YY1/PIWIL4 axis. Mol Carcinog. 2023;62(4):427–437. doi:10.1002/mc.23496.
   PubMed Web of Science ®Google Scholar
• Huang X, Zhou W, Zhang Y. Transcription factor YY1 enhances the stemness of lung cancer cells by stabilizing hypoxia factor HIF-1α under a hypoxic microenvironment. Environ Toxicol. 2021;36(1):114–122. doi:10.1002/tox.23017.
   PubMed Web of Science ®Google Scholar
• Huang T, Wang G, Yang L, Peng B, Wen Y, Ding G, Wang Z. Transcription factor YY1 modulates lung cancer progression by activating lncRNA-PVT1. DNA Cell Biol. 2017;36(11):947–958. doi:10.1089/dna.2017.3857.
   PubMed Web of Science ®Google Scholar
• Yang R, Liu Z, Cao H, Shi Y. LINC01089, suppressed by YY1, inhibits lung cancer progression by targeting miR-301b-3p/HPDG axis. Cell Biol Toxicol. 2022;38(6):1063–1077. doi:10.1007/s10565-021-09643-8.
   PubMed Web of Science ®Google Scholar
• Zheng JY, Zhu T, Zhuo W, Mao XY, Yin JY, Li X, He Y-J, Zhang W, Liu C, Liu Z-Q, et al. eIf3a sustains non-small cell lung cancer stem cell-like properties by promoting YY1-mediated transcriptional activation of β-catenin. Biochem Pharmacol. 2023;213:115616. doi:10.1016/j.bcp.2023.115616.
   PubMed Web of Science ®Google Scholar
• Wang Y, Ma R, Liu B, Kong J, Lin H, Yu X, Wang R, Li L, Gao M, Zhou B, et al. SNP rs17079281 decreases lung cancer risk through creating an YY1-binding site to suppress DCBLD1 expression. Oncogene. 2020;39(20):4092–4102. doi:10.1038/s41388-020-1278-4.
   PubMed Web of Science ®Google Scholar